Avalyn's upsized IPO; Alector ends another study in GSK partnership

April 30, 2026 11:33 AM EDT News Briefing Ava­lyn's up­sized IPO; Alec­tor ends an­oth­er study in GSK part­ner­ship; Teva's $700M buy ENDPOINTS 🔔 Ava­lyn Phar­ma’s $300M IPO: The Boston, MA-based biotech is sell­ing over 16.5 mil­lion shares at $18 apiece. The com­pa­ny is … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER